Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC

Front Oncol. 2023 Jul 5:13:1217424. doi: 10.3389/fonc.2023.1217424. eCollection 2023.


Introduction: The introduction of consolidation immunotherapy after chemoradiotherapy has improved outcome for patients with locally advanced non-small cell lung cancer. However, not all patients receive this treatment. This study identifies factors associated with failure to start durvalumab as consolidation therapy with the aim of optimizing treatment, supportive care and prehabilitation to ensure that more patients complete the planned treatment.

Materials and methods: Patients from two clinical trials and a named patient use program, were included in this study. All patients received platinum-doublet chemotherapy concomitant with radiotherapy to a total dose of 60-66 gray. Patient characteristics, cancer treatment, toxicity, performance status and laboratory data before and after chemoradiotherapy were recorded and patients who never started durvalumab were compared with those who did.

Results: A total of 101 patients were included, of which 83 started treatments with durvalumab after chemoradiotherapy. The 18 patients who did not start durvalumab had significantly higher lactate dehydrogenase at baseline and a worse performance status, cumulative toxicity and higher c-reactive protein after completed chemoradiotherapy. Data also suggest that pre-treatment diabetes and reduced hemoglobin and/or diffusion capacity of the lungs for carbon monoxide contribute to the risk of treatment abruption.

Conclusion: Treatment plan disruption rate was 18%. Systemic inflammation and performance status were associated with failure to receive durvalumab after chemoradiation. Further studies are needed to confirm findings and prospective trials should investigate whether prehabilitation and supportive treatment could help more patients finishing the planned treatment.

Clinical trial registration: clinicaltrials.gov, identifier NCT03798535; NCT04392505.

Keywords: chemoradiotherapy; durvalumab; non-small cell lung cancer; personalized treatment; prehabilitation; toxicity.

Associated data

  • ClinicalTrials.gov/NCT03798535
  • ClinicalTrials.gov/NCT04392505

Grants and funding

The DART trial is supported by the South-Eastern Norway Regional Health Authority (grant no: 2019119 and 26011) and by Astra Zeneca. The name patient use program and the PACIFIC-R trial were run by Astra Zeneca.